:

Research Programs > CancerCenterClinicalTrials
Cancer Center Clinical Trials

Official Title:ECOG 2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide Alone and in Combination with Epoetin Alfa in Subjects with Low- or Intermediate-1 Risk myelodysplastic syndrome (MDS) and Sympt
Date Window: 10/27/2009 - 10/27/2014
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:To test how well lenalidomide works with or without epoetin alfa to treat anemia in patients with myelodysplastic syndrome.

ClinicalTrials.gov identifier
NCT00843882


Official Title:CALGB 30801: A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition In COX-2 Expressing Advanced Non-Small Cell Lung Cancer
Date Window: 6/8/2010 - 6/8/2015
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:
ClinicalTrials.gov identifier
NCT01041781

Official Title:CALGB 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Date Window: 12/8/2010 - 12/8/2015
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:To compare the effectiveness of 6 versus 12 courses of standard chemotherapy after surgery for stage III colon cancer; and to test how well celecoxib works at preventing colon cancer recurrence when added to chemotherapy.

 

ClinicalTrials.gov identifier
NCT01150045

 

 


Official Title:CALGB 80802: Phase III Randomized Study of Sorafenib plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
Date Window: 6/12/2012 - 6/12/2017
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:
To test how well chemotherapy works to treat advanced liver cancer when added to standard sorafenib treatment.

ClinicalTrials.gov identifier
NCT01015833


Official Title:ECOG 2906: Phase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos
Date Window: 11/26/2012 - 11/26/2017
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:
To compare the effectiveness of clofarabine to standard induction chemotherapy, and to test the effectiveness of decitabine as maintenance therapy, in patients over age 60 with acute myelogenous leukemia.

ClinicalTrials.gov identifier
NCT01041703


Official Title:ECOG 1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)
Date Window: 11/19/2012 - 11/19/2017
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:
To test how well bevacizumab works to prevent lung cancer recurrence when added to standard chemotherapy after complete surgical resection of non small cell lung cancer.

ClinicalTrials.gov identifier
NCT00324805


Official Title:SWOG 1007 (RxPONDER trial): A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or
Date Window: 9/6/2012 - 9/6/2017
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:
To compare the effectiveness of hormonal therapy with or without chemotherapy in patients with 1-3 positive lymph nodes and an Oncotype recurrence score of 25 or less.

 
ClinicalTrials.gov identifier
NCT01272037


Seeking Patients with Asymptomatic Smoldering Multiple Myeloma for Lenalidomide Test Trial
Official Title:ECOG 3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic Smoldering Multiple Myeloma
Date Window: 11/21/2012 - 11/21/2017
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:To test how well lenalidomide works to treat asymptomatic smoldering multiple

ClinicalTrials.gov identifier
NCT01169337


Help your fellow caregivers and loved ones! If you care for a service member or veteran who had a TBI after October 2001 while serving in the Military, you may be eligible to participate.
Official Title:Health-Related Quality of Life in Caregivers of Service Members and Veterans with Traumatic Brain Injury
Date Window: 4/26/2013 - 8/15/2015
Contact for Details:If you or someone you know may be interested please call 1-855 821-1469, email caregiver.study@dvbic.org, or view our flyer by clicking this link: The Caregiver Study.
Summary:​​​​​​If you care for a service member of veteran who had a TBI after Ocober 2001 while serving in the military, you may be eligibile to participate. Participation may include the completion of web-based self-report measures, a small group discussion, a telephone interview, and/or completing a new quality of life measure online. Most of these procedures can be done from the comfort of your home. The total time commitment will be about 1-3 hours each year for up to 3 years. Additionally, you may be compensated for your participation.

Help your fellow service members and veterans!
Official Title:Exploring the Natural History of Traumatic Brain Injury within a Military Cohort – A Longitudinal Database and Blood Banking Study
Date Window: 4/26/2013 - 4/1/2028
Contact for Details:For more information please call 855-753-3394 or email natural.history1@dvbic.org
Summary:​​If you served in the military after October 2001, you may be eligible to participate in a reserach study requested by Congress. We are currently recruiting service members and veterans who 1) have incurred a TBI since 2001, 2) incurred a bodily injury that was not a TBI since 2011 or 3) have served at any point since 2001 but were not injured.

The purpose of the study is to increase our understanding of the long term effects of trumatic brain injury on service members and veterans. Participation will include short yearly appointments. Each visit will last either 2 hours or 2 days and will occure once per year for up to 15 years. You may elect to participate only in web-based and telephone measures. 

Your participant could contribute to knowledge that could improve the care of your fellow service members and veterans. You may be compensated for your participation.


1 - 10 Next

Contact

Location
Building 17B
3rd Floor, Suite E

Phone
Main (301) 295-8239/8219

Hours of Operation
Monday thru Friday
0700 - 1630